mRNA-1608 / Moderna - LARVOL DELTA

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes (clinicaltrials.gov) - P1/2 | N=365 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Herpes Simplex • Infectious Disease

Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. (PubMed, Viruses) - "Notably, several vaccines-SL-V20, HF10, VC2, and mRNA-1608-have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections."

Journal • Review • Herpes Simplex • Infectious Disease

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes (clinicaltrials.gov) - P1/2 | N=365 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Herpes Simplex • Infectious Disease

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes (clinicaltrials.gov) - P1/2 | N=300 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Herpes Simplex • Infectious Disease